Table 4 Therapeutic management and outcome of patients with and without TIVAP (totally implanted venous access port)-related infection
Characteristic | All patients n = 151 | TIVAP-related infections n = 68 | No TIVAP-related infections n = 83 | p value |
|---|---|---|---|---|
Time between ICU admission and TIVAP withdrawal, days | 1 (0–2) | 1 (0–1) | 1 (0–2) | 0.09 |
Antibiotics | ||||
 Beta lactam antibiotic, n (%) | 143 (95) | 63 (93) | 80 (96) | 0.49 |
 Glycopeptide/linezolid, n (%) | 78 (52) | 38 (57) | 40 (48) | 0.29 |
Use of MV, n (%) | 74 (49) | 24 (35) | 50 (60) | < 0.01 |
MV duration, days | 0 (0–5) | 0 (0–3) | 2 (0–7) | 0.26 |
Vasopressors, n (%) | 103 (68) | 37 (55) | 66 (80) | < 0.01 |
Vasopressors, days | 2 (0–3) | 1 (0–2) | 2 (1–4) | 0.04 |
ICU length of stay, days | 5 (3–10) | 4 (3–6) | 6 (3–12) | 0.40 |
ICU mortality, n (%) | 39 (26) | 6 (9) | 33 (40) | < 0.01 |
28-day mortality, n (%) | 54 (36) | 14 (20.5) | 40 (48) | < 0.01 |
6-Month mortality, n (%) | 89 (59) | 34 (50) | 55 (66) | 0.04 |